Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T Cells

Rosa Bacchetta, Barbarella Lucarelli, Claudia Sartirana, Silvia Gregori, Maria T. Lupo Stanghellini, Patrick Miqueu, Stefan Tomiuk, Maria Hernandez-Fuentes, Monica E. Gianolini, Raffaella Greco, Massimo Bernardi, Elisabetta Zappone, Silvano Rossini, Uwe Janssen, Alessandro Ambrosi, Monica Salomoni, Jacopo Peccatori, Fabio Ciceri, Maria Grazia Roncarolo

Research output: Contribution to journalArticle

Abstract

T-cell therapy after hematopoietic stem cell transplantation (HSCT) has been used alone or in combination with immunosuppression to cure hematologic malignancies and to prevent disease recurrence. Here, we describe the outcome of patients with high-risk/advanced stage hematologic malignancies, who received T-cell depleted (TCD) haploidentical-HSCT (haplo-HSCT) combined with donor T lymphocytes pretreated with IL-10 (ALT-TEN trial). IL-10-anergized donor T cells (IL-10-DLI) contained T regulatory type 1 (Tr1) cells specific for the host alloantigens, limiting donor-vs.-host-reactivity, and memory T cells able to respond to pathogens. IL-10-DLI were infused in 12 patients with the goal of improving immune reconstitution after haplo-HSCT without increasing the risk of graft-versus-host-disease (GvHD). IL-10-DLI led to fast immune reconstitution in five patients. In four out of the five patients, total T-cell counts, TCR-Vß repertoire and T-cell functions progressively normalized after IL-10-DLI. These four patients are alive, in complete disease remission and immunosuppression-free at 7.2 years (median follow-up) after haplo-HSCT. Transient GvHD was observed in the immune reconstituted (IR) patients, despite persistent host-specific hypo-responsiveness of donor T cells in vitro and enrichment of cells with Tr1-specific biomarkers in vivo. Gene-expression profiles of IR patients showed a common signature of tolerance. This study provides the first indication of the feasibility of Tr1 cell-based therapy and paves way for the use of these Tr1 cells as adjuvant treatment for malignancies and immune-mediated disorders.

Original languageEnglish
Article numberArticle 16
JournalFrontiers in Immunology
Volume5
Issue numberJAN
DOIs
Publication statusPublished - 2014

Fingerprint

Interleukin-10
Tissue Donors
T-Lymphocytes
Regulatory T-Lymphocytes
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Hematologic Neoplasms
Cell- and Tissue-Based Therapy
Immunosuppression
Isoantigens
Immune System Diseases
Transcriptome
Cell Count
Biomarkers
Recurrence
Neoplasms

Keywords

  • Cell therapy
  • Haploidentical
  • Hematopoietic stem cell transplantation
  • IL-10
  • T regulatory type 1 cells
  • Tolerance

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T Cells. / Bacchetta, Rosa; Lucarelli, Barbarella; Sartirana, Claudia; Gregori, Silvia; Lupo Stanghellini, Maria T.; Miqueu, Patrick; Tomiuk, Stefan; Hernandez-Fuentes, Maria; Gianolini, Monica E.; Greco, Raffaella; Bernardi, Massimo; Zappone, Elisabetta; Rossini, Silvano; Janssen, Uwe; Ambrosi, Alessandro; Salomoni, Monica; Peccatori, Jacopo; Ciceri, Fabio; Roncarolo, Maria Grazia.

In: Frontiers in Immunology, Vol. 5, No. JAN, Article 16, 2014.

Research output: Contribution to journalArticle

Bacchetta, R, Lucarelli, B, Sartirana, C, Gregori, S, Lupo Stanghellini, MT, Miqueu, P, Tomiuk, S, Hernandez-Fuentes, M, Gianolini, ME, Greco, R, Bernardi, M, Zappone, E, Rossini, S, Janssen, U, Ambrosi, A, Salomoni, M, Peccatori, J, Ciceri, F & Roncarolo, MG 2014, 'Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T Cells', Frontiers in Immunology, vol. 5, no. JAN, Article 16. https://doi.org/10.3389/fimmu.2014.00016
Bacchetta, Rosa ; Lucarelli, Barbarella ; Sartirana, Claudia ; Gregori, Silvia ; Lupo Stanghellini, Maria T. ; Miqueu, Patrick ; Tomiuk, Stefan ; Hernandez-Fuentes, Maria ; Gianolini, Monica E. ; Greco, Raffaella ; Bernardi, Massimo ; Zappone, Elisabetta ; Rossini, Silvano ; Janssen, Uwe ; Ambrosi, Alessandro ; Salomoni, Monica ; Peccatori, Jacopo ; Ciceri, Fabio ; Roncarolo, Maria Grazia. / Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T Cells. In: Frontiers in Immunology. 2014 ; Vol. 5, No. JAN.
@article{d850595475394be2b8673ad9a2d99ac4,
title = "Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T Cells",
abstract = "T-cell therapy after hematopoietic stem cell transplantation (HSCT) has been used alone or in combination with immunosuppression to cure hematologic malignancies and to prevent disease recurrence. Here, we describe the outcome of patients with high-risk/advanced stage hematologic malignancies, who received T-cell depleted (TCD) haploidentical-HSCT (haplo-HSCT) combined with donor T lymphocytes pretreated with IL-10 (ALT-TEN trial). IL-10-anergized donor T cells (IL-10-DLI) contained T regulatory type 1 (Tr1) cells specific for the host alloantigens, limiting donor-vs.-host-reactivity, and memory T cells able to respond to pathogens. IL-10-DLI were infused in 12 patients with the goal of improving immune reconstitution after haplo-HSCT without increasing the risk of graft-versus-host-disease (GvHD). IL-10-DLI led to fast immune reconstitution in five patients. In four out of the five patients, total T-cell counts, TCR-V{\ss} repertoire and T-cell functions progressively normalized after IL-10-DLI. These four patients are alive, in complete disease remission and immunosuppression-free at 7.2 years (median follow-up) after haplo-HSCT. Transient GvHD was observed in the immune reconstituted (IR) patients, despite persistent host-specific hypo-responsiveness of donor T cells in vitro and enrichment of cells with Tr1-specific biomarkers in vivo. Gene-expression profiles of IR patients showed a common signature of tolerance. This study provides the first indication of the feasibility of Tr1 cell-based therapy and paves way for the use of these Tr1 cells as adjuvant treatment for malignancies and immune-mediated disorders.",
keywords = "Cell therapy, Haploidentical, Hematopoietic stem cell transplantation, IL-10, T regulatory type 1 cells, Tolerance",
author = "Rosa Bacchetta and Barbarella Lucarelli and Claudia Sartirana and Silvia Gregori and {Lupo Stanghellini}, {Maria T.} and Patrick Miqueu and Stefan Tomiuk and Maria Hernandez-Fuentes and Gianolini, {Monica E.} and Raffaella Greco and Massimo Bernardi and Elisabetta Zappone and Silvano Rossini and Uwe Janssen and Alessandro Ambrosi and Monica Salomoni and Jacopo Peccatori and Fabio Ciceri and Roncarolo, {Maria Grazia}",
year = "2014",
doi = "10.3389/fimmu.2014.00016",
language = "English",
volume = "5",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
number = "JAN",

}

TY - JOUR

T1 - Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T Cells

AU - Bacchetta, Rosa

AU - Lucarelli, Barbarella

AU - Sartirana, Claudia

AU - Gregori, Silvia

AU - Lupo Stanghellini, Maria T.

AU - Miqueu, Patrick

AU - Tomiuk, Stefan

AU - Hernandez-Fuentes, Maria

AU - Gianolini, Monica E.

AU - Greco, Raffaella

AU - Bernardi, Massimo

AU - Zappone, Elisabetta

AU - Rossini, Silvano

AU - Janssen, Uwe

AU - Ambrosi, Alessandro

AU - Salomoni, Monica

AU - Peccatori, Jacopo

AU - Ciceri, Fabio

AU - Roncarolo, Maria Grazia

PY - 2014

Y1 - 2014

N2 - T-cell therapy after hematopoietic stem cell transplantation (HSCT) has been used alone or in combination with immunosuppression to cure hematologic malignancies and to prevent disease recurrence. Here, we describe the outcome of patients with high-risk/advanced stage hematologic malignancies, who received T-cell depleted (TCD) haploidentical-HSCT (haplo-HSCT) combined with donor T lymphocytes pretreated with IL-10 (ALT-TEN trial). IL-10-anergized donor T cells (IL-10-DLI) contained T regulatory type 1 (Tr1) cells specific for the host alloantigens, limiting donor-vs.-host-reactivity, and memory T cells able to respond to pathogens. IL-10-DLI were infused in 12 patients with the goal of improving immune reconstitution after haplo-HSCT without increasing the risk of graft-versus-host-disease (GvHD). IL-10-DLI led to fast immune reconstitution in five patients. In four out of the five patients, total T-cell counts, TCR-Vß repertoire and T-cell functions progressively normalized after IL-10-DLI. These four patients are alive, in complete disease remission and immunosuppression-free at 7.2 years (median follow-up) after haplo-HSCT. Transient GvHD was observed in the immune reconstituted (IR) patients, despite persistent host-specific hypo-responsiveness of donor T cells in vitro and enrichment of cells with Tr1-specific biomarkers in vivo. Gene-expression profiles of IR patients showed a common signature of tolerance. This study provides the first indication of the feasibility of Tr1 cell-based therapy and paves way for the use of these Tr1 cells as adjuvant treatment for malignancies and immune-mediated disorders.

AB - T-cell therapy after hematopoietic stem cell transplantation (HSCT) has been used alone or in combination with immunosuppression to cure hematologic malignancies and to prevent disease recurrence. Here, we describe the outcome of patients with high-risk/advanced stage hematologic malignancies, who received T-cell depleted (TCD) haploidentical-HSCT (haplo-HSCT) combined with donor T lymphocytes pretreated with IL-10 (ALT-TEN trial). IL-10-anergized donor T cells (IL-10-DLI) contained T regulatory type 1 (Tr1) cells specific for the host alloantigens, limiting donor-vs.-host-reactivity, and memory T cells able to respond to pathogens. IL-10-DLI were infused in 12 patients with the goal of improving immune reconstitution after haplo-HSCT without increasing the risk of graft-versus-host-disease (GvHD). IL-10-DLI led to fast immune reconstitution in five patients. In four out of the five patients, total T-cell counts, TCR-Vß repertoire and T-cell functions progressively normalized after IL-10-DLI. These four patients are alive, in complete disease remission and immunosuppression-free at 7.2 years (median follow-up) after haplo-HSCT. Transient GvHD was observed in the immune reconstituted (IR) patients, despite persistent host-specific hypo-responsiveness of donor T cells in vitro and enrichment of cells with Tr1-specific biomarkers in vivo. Gene-expression profiles of IR patients showed a common signature of tolerance. This study provides the first indication of the feasibility of Tr1 cell-based therapy and paves way for the use of these Tr1 cells as adjuvant treatment for malignancies and immune-mediated disorders.

KW - Cell therapy

KW - Haploidentical

KW - Hematopoietic stem cell transplantation

KW - IL-10

KW - T regulatory type 1 cells

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=84895561909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895561909&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2014.00016

DO - 10.3389/fimmu.2014.00016

M3 - Article

AN - SCOPUS:84895561909

VL - 5

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - JAN

M1 - Article 16

ER -